MARS Bioimaging, a New Zealand–headquartered medical device company, today announced that it has sold a mobile photon-counting CT scanner to Bracco I...
•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operati...
Creates Standalone Leader in Advanced Therapy Manufacturing with Decades of Proven Experience and Continued Commitment to Client Service Dedicated Resou...
Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505(b)(2) Pathways, and CNS Countermeasure Applicati...
Deal builds upon UCB’s position as a leader in immunology innovation and expands capabilities in next-generation biologics with potential for i...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has signed a definitive agreement to sell its microbiol...
Sun Pharmaceutical Industries Limitedand Organon & Co. announced that they have entered into a definitive agreement under which Sun Pharma will acqui...
Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade gl...
Alcami Corporation (“Alcami”), a leading U.S.-based contract development and manufacturing organization (CDMO), announced it has entered into...
Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory mul...
Charles River Laboratories International, Inc. has announced the successful completion of its acquisition of PathoQuest, a specialist in ne...
This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipeline Under the terms of the agreement, Nxe...
Global pharma major Lupin Limited (Lupin) announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pha...
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pip...
© 2026 Biopharma Boardroom. All Rights Reserved.
